Science 🧬Snacks: Tesamorelin, Women & Hormones — What the Data Actually Says

The following is a summary of published research literature for educational purposes only. CDJ Peppers LLC is not a medical provider. Nothing in this article constitutes medical advice or a recommendation to use any compound. Consult a licensed physician before making any health decisions.

There’s a lot of noise online right now about tesamorelin being “dangerous for women.”So let’s bring this back to what the clinical literature actually shows.

Women WERE included in the trials

Tesamorelin isn’t just studied in men.

In the two pivotal phase III clinical trials used for FDA approval:

• There were 816 total participants

• About 14–16% were women

• That’s roughly 115–130 women included in the data

And here’s the key part:

👉 Subgroup analysis by gender showed no statistically significant differences in:

• Visceral fat reduction

• IGF-1 response

So based on the available clinical data, women did not have worse outcomes.

Let’s clear up the biggest myth: visceral fat

There’s a narrative going around that:

“It’s dangerous for women to lose visceral fat.”

That’s simply not supported by evidence.

Visceral fat (fat around your organs) is associated with:

• Insulin resistance

• Cardiovascular disease

In clinical studies, the primary endpoint measured was reduction of visceral adipose tissue.

Where caution actually comes in: IGF-1

Tesamorelin works by:

• Stimulating growth hormone (GH)

• Increasing IGF-1

That’s expected—but it’s also where monitoring matters.

According to FDA prescribing information:

• Tesamorelin raises IGF-1 levels

• The effects of long-term elevated IGF-1 are not fully understood

• Clinicians are advised to monitor IGF-1 during therapy and consider stopping if levels remain high

In clinical trials:

• A significant percentage of patients had IGF-1 levels above normal ranges during treatment

👉 Translation:This isn’t about “fear”—it’s about not ignoring your labs.

Does tesamorelin raise testosterone in women?

Another common claim is that tesamorelin:

“Increases androgens” or “acts like a steroid”

This is not supported by clinical data.

Tesamorelin works through:

• The GH/IGF-1 axis

  
  

  —not androgen pathways

There’s no evidence showing:

• Dangerous increases in testosterone

• Virilization effects in women

Where nuance DOES matter

This is where we keep it honest.

Tesamorelin increases IGF-1, and IGF-1 overlaps with:

• Insulin signaling

• Ovarian hormone signaling

So in certain contexts—like:

• PCOS

• Insulin resistance

👉 You could theoretically amplify existing hormonal tendencies

But that’s:

• Context-dependent

• Not a direct androgen effect

• Not shown as a clinical safety signal

Tesamorelin vs. “research peptides”

The clinical evidence base for tesamorelin differs significantly from that of other GH secretagogues studied in the literature. Not all GH secretagogues are equal.

Tesamorelin:

• FDA-approved

• Backed by phase III clinical trials

• Has defined safety monitoring (like IGF-1)

Other compounds (like CJC-1295/ipamorelin):

• Act on similar pathways

• But have less clinical data and less predictability

Same axis ≠ same evidence.

The bottom line

In clinical studies, tesamorelin demonstrated a statistically significant reduction in visceral adipose tissue compared to placebo. If you strip away the internet noise, the evidence-based take is simple:

• Women were included in tesamorelin trials (~14–16%)

• No female-specific harm signal was identified

• Visceral fat loss is beneficial, not dangerous

• Tesamorelin does not directly increase androgens

• And the real key is monitoring IGF-1 and metabolic health

Final thought

This isn’t about fear—it’s about context and responsibility.

Tesamorelin isn’t “dangerous for women.” But like anything that affects hormone signaling:

👉 Clinical protocols include monitoring of IGF-1 levels during therapy.